Meyler's Side Effects of Endocrine and Metabolic Drugs

1. Auflage 2009
ISBN: 978-0-08-093292-7
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 708 Seiten

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Endocrine and metabolic diseases are common, includes diseases such as diabetes, thyroid disease, and obesity. Endocrinologists, including diabetes professionals, internal medicine and primary care practitioners, obstetricians and gynecologists, and others will find this book useful when treating endocrine or metabolic diseases. The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler's Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been designated by their recommended or proposed International Non-proprietary Names (rINN or pINN), when those are not available, clinical names have been used. In some cases, brand names have been used. This volume is critical for any health professional involved in the administration of endocrine and metabolics mediations.

Surpasses the Physician's Desk Reference ? by including clinical case studies and independent expert analysis Complete index of drug names Most complete cross referencing of drug-drug interactions available Extensive references to primary and secondary literature Also includes information on adverse effects in pregnancy The book is divided into eight sections: Corticosteroids and related drugs Prostaglandins Sex hormones and related drugs Iodine and drugs that affect thyroid function Insulin and other hypoglycemic drugs Other hormones and related drugs Lipid-regulated drugs Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs

Autoren/Hrsg.

Inhaltsverzeichnis

1;Front Cover;1
2;Meyler's Side Effects of Endocrine and Metabolic Drugs;4
3;Copyright Page;5
4;Table of Contents;6
5;Preface;8
6;Section 1 Corticosteroids and related drugs;12
6.1;Chapter 1 Corticorelin (corticotropin-releasing hormone (CRH));14
6.1.1;General Information;14
6.1.2;References;14
6.2;Chapter 2 Corticosteroids—glucocorticoids;14
6.2.1;General Information;14
6.2.2;Organs and Systems;17
6.2.3;Long-Term Effects;50
6.2.4;Second-Generation Effects;52
6.2.5;Susceptibility Factors;56
6.2.6;Drug Administration;57
6.2.7;Drug–Drug Interactions;64
6.2.8;Diagnosis of adverse drug reactions;65
6.2.9;Management of adverse drug reactions;66
6.2.10;References;66
6.3;Chapter 3 Corticosteroids—glucocorticoids, inhaled;81
6.3.1;General Information;81
6.3.2;Organs and Systems;84
6.3.3;Second-Generation Effects;98
6.3.4;Drug–Drug Interactions;98
6.3.5;References;99
6.4;Chapter 4 Corticosteroids—glucocorticoids, topical;104
6.4.1;References;104
6.5;Chapter 5 Corticosteroids—mineralocorticoids;105
6.5.1;General Information;105
6.5.2;Organs and Systems;105
6.5.3;Drug–Drug Interactions;105
6.5.4;References;105
6.6;Chapter 6 Corticotrophins (corticotropin and tetracosactide);106
6.6.1;General Information;106
6.6.2;Organs and Systems;106
6.6.3;Long-Term Effects;108
6.6.4;Second-Generation Effects;108
6.6.5;Susceptibility Factors;109
6.6.6;Drug–Drug Interactions;109
6.6.7;References;109
7;Section 2 Prostaglandins;112
7.1;General Information;114
7.2;Organs and Systems;118
7.3;Second-Generation Effects;118
7.4;Susceptibility Factors;118
7.5;Drug Administration;119
7.6;References;120
7.7;Chapter 7 Alprostadil;123
7.7.1;General Information;123
7.7.2;Organs and Systems;123
7.7.3;References;126
7.8;Chapter 8 Beraprost;127
7.8.1;General Information;127
7.8.2;Reference;127
7.9;Chapter 9 Bimatoprost;127
7.9.1;General Information;127
7.9.2;Organs and Systems;127
7.9.3;References;127
7.10;Chapter 10 Carboprost;127
7.10.1;General Information;127
7.10.2;Organs and Systems;127
7.10.3;Drug Administration;127
7.10.4;References;128
7.11;Chapter 11 Dinoprostone;128
7.11.1;General Information;128
7.11.2;Organs and Systems;128
7.11.3;Reference;128
7.12;Chapter 12 Enprostil;128
7.12.1;General Information;128
7.12.2;Organs and Systems;128
7.12.3;Reference;128
7.13;Chapter 13 Epoprostenol;128
7.13.1;General Information;128
7.13.2;Organs and Systems;129
7.13.3;Drug-drug interactions;130
7.13.4;Management of adverse drug reactions;130
7.13.5;References;130
7.14;Chapter 14 Gemeprost;131
7.14.1;General Information;131
7.14.2;Organs and Systems;131
7.14.3;References;131
7.15;Chapter 15 Iloprost;131
7.15.1;General Information;131
7.15.2;Organs and Systems;132
7.15.3;Drug Administration;133
7.15.4;References;133
7.16;Chapter 16 Latanoprost;133
7.16.1;General Information;133
7.16.2;Organs and Systems;133
7.16.3;Second-Generation Effects;137
7.16.4;Drug-drug interactions;137
7.16.5;References;137
7.17;Chapter 17 Misoprostol;138
7.17.1;General Information;138
7.17.2;Organs and Systems;140
7.17.3;Second-Generation Effects;140
7.17.4;Drug Administration;142
7.17.5;References;142
7.18;Chapter 18 Sulprostone;144
7.18.1;General Information;144
7.18.2;Organs and Systems;144
7.18.3;References;145
7.19;Chapter 19 Travoprost;145
7.19.1;General Information;145
7.19.2;Organs and Systems;145
7.19.3;References;145
7.20;Chapter 20 Unoprostone;145
7.20.1;General Information;145
7.20.2;Organs and Systems;145
7.20.3;Reference;145
8;Section 3 Sex hormones and related drugs;146
8.1;Chapter 21 Androgens and anabolic steroids;148
8.1.1;General Information;148
8.1.2;Organs and Systems;150
8.1.3;Long-Term Effects;153
8.1.4;Second-Generation Effects;155
8.1.5;Susceptibility Factors;155
8.1.6;Drug Administration;156
8.1.7;Drug–Drug Interactions;157
8.1.8;References;157
8.2;Chapter 22 Antiandrogens;160
8.2.1;General Information;160
8.2.2;Organs and Systems;163
8.2.3;Long-Term Effects;166
8.2.4;Susceptibility factors;166
8.2.5;Drug Administration;166
8.2.6;Drug-drug interactions;167
8.2.7;Interference with diagnostic routines;167
8.2.8;References;167
8.3;Chapter 23 Aromatase inhibitors;170
8.3.1;General Information;170
8.3.2;Organs and Systems;170
8.3.3;Long-Term Effects;171
8.3.4;Susceptibility Factors;172
8.3.5;Drug-Drug Interactions;172
8.3.6;References;172
8.4;Chapter 24 Chlorotrianisene;173
8.4.1;General Information;173
8.4.2;Organs and Systems;174
8.4.3;References;174
8.5;Chapter 25 Clomiphene;174
8.5.1;General Information;174
8.5.2;Organs and Systems;174
8.5.3;Long-Term Effects;174
8.5.4;Second-Generation Effects;175
8.5.5;References;175
8.6;Chapter 26 Cyclofenil;176
8.6.1;General Information;176
8.6.2;Organs and Systems;176
8.6.3;References;176
8.7;Chapter 27 Danazol;176
8.7.1;General Information;176
8.7.2;Organs and Systems;176
8.7.3;References;177
8.8;Chapter 28 Diethylstilbestrol;177
8.8.1;General Information;177
8.8.2;Organs and Systems;177
8.8.3;Long-Term Effects;178
8.8.4;Second-Generation Effects;178
8.8.5;Drug Administration;182
8.8.6;References;182
8.9;Chapter 29 Estrogens;183
8.9.1;General Information;183
8.9.2;Organs and Systems;185
8.9.3;Long-Term Effects;189
8.9.4;Second-Generation Effects;201
8.9.5;Susceptibility Factors;201
8.9.6;Drug Administration;202
8.9.7;References;204
8.10;Chapter 30 Gonadotropins;211
8.10.1;General Information;211
8.10.2;Organs and Systems;212
8.10.3;Long-Term Effects;214
8.10.4;Second-Generation Effects;216
8.10.5;Drug Administration;216
8.10.6;References;217
8.11;Chapter 31 Hormonal contraceptives—emergency contraception;219
8.11.1;General Information;219
8.11.2;Organs and Systems;221
8.11.3;Second-Generation Effects;221
8.11.4;Susceptibility Factors;221
8.11.5;References;221
8.12;Chapter 32 Hormonal contraceptives—intracervical and intravaginal;222
8.12.1;General Information;222
8.12.2;References;222
8.13;Chapter 33 Hormonal contraceptives—male;223
8.13.1;General Information;223
8.13.2;Organs and Systems;223
8.13.3;References;223
8.14;Chapter 34 Hormonal contraceptives—oral;224
8.14.1;General Information;224
8.14.2;Organs and Systems;226
8.14.3;Long-Term Effects;246
8.14.4;Second-Generation Effects;247
8.14.5;Susceptibility Factors;248
8.14.6;Drug Administration;249
8.14.7;Drug–Drug Interactions;250
8.14.8;Smoking;253
8.14.9;References;253
8.15;Chapter 35 Hormonal contraceptives—progestogen injections;263
8.15.1;General Information;263
8.15.2;References;264
8.16;Chapter 36 Hormonal contraceptives—progestogen implants;264
8.16.1;General Information;264
8.16.2;Organs and Systems;267
8.16.3;Second-Generation Effects;268
8.16.4;Drug Administration;268
8.16.5;References;269
8.17;Chapter 37 Hormonal contraceptives—transdermal;270
8.17.1;Reference;270
8.18;Chapter 38 Hormone replacement therapy—estrogens;270
8.18.1;General Information;270
8.18.2;Organs and Systems;272
8.18.3;Long-Term Effects;277
8.18.4;Susceptibility Factors;277
8.18.5;Drug Administration;278
8.18.6;Drug–Drug Interactions;280
8.18.7;Food-Drug Interactions;281
8.18.8;References;281
8.19;Chapter 39 Hormonal replacement therapy—estrogens + androgens;284
8.19.1;General Information;284
8.19.2;References;285
8.20;Chapter 40 Hormone replacement therapy—estrogens + progestogens;285
8.20.1;General Information;285
8.20.2;Organs and Systems;287
8.20.3;Long-Term Effects;289
8.20.4;Susceptibility Factors;289
8.20.5;Drug Administration;290
8.20.6;Drug–Drug Interactions;290
8.20.7;References;290
8.21;Chapter 41 Medroxyprogesterone;292
8.21.1;General Information;292
8.21.2;Organs and Systems;292
8.21.3;Long-Term Effects;294
8.21.4;Second-Generation Effects;294
8.21.5;Susceptibility Factors;294
8.21.6;Drug Administration;294
8.21.7;References;295
8.22;Chapter 42 Mifepristone;296
8.22.1;General Information;296
8.22.2;Organs and Systems;297
8.22.3;Long-Term Effects;298
8.22.4;Second-Generation Effects;298
8.22.5;Drug Administration;298
8.22.6;References;298
8.23;Chapter 43 Progestogens;299
8.23.1;General Information;299
8.23.2;Organs and Systems;301
8.23.3;Long-Term Effects;303
8.23.4;Second-Generation Effects;303
8.23.5;Drug Administration;304
8.23.6;Drug-drug interactions;306
8.23.7;References;306
8.24;Chapter 44 Raloxifene;308
8.24.1;General Information;308
8.24.2;Organs and Systems;309
8.24.3;Susceptibility factors;310
8.24.4;Drug–Drug Interactions;310
8.24.5;References;310
8.25;Chapter 45 Tamoxifen;312
8.25.1;General Information;312
8.25.2;Organs and Systems;314
8.25.3;Long-Term Effects;318
8.25.4;Second-Generation Effects;320
8.25.5;Susceptibility Factors;320
8.25.6;Drug–Drug Interactions;320
8.25.7;Drug–Procedure Interactions;320
8.25.8;Management of adverse drug reactions;321
8.25.9;References;321
8.26;Chapter 46 Tibolone;325
8.26.1;General Information;325
8.26.2;Organ and Systems;325
8.26.3;Drug-drug interactions;325
8.26.4;References;325
9;Section 4 Iodine and drugs that affect thyroid function;326
9.1;Chapter 47 Iodine-containing medicaments;328
9.1.1;General Information;328
9.1.2;Organs and Systems;330
9.1.3;Second-Generation Effects;332
9.1.4;Drug Administration;332
9.1.5;Interference with Diagnostic Tests;333
9.1.6;References;333
9.2;Chapter 48 Iodine radioactive;335
9.2.1;General Information;335
9.2.2;Organs and Systems;335
9.2.3;Long-Term Effects;336
9.2.4;Second-Generation Effects;337
9.2.5;Interference with Diagnostic Tests;338
9.2.6;References;338
9.3;Chapter 49 Polyvidone and povidone-iodine;339
9.3.1;General Information;339
9.3.2;Organs and Systems;340
9.3.3;Second-Generation Effects;342
9.3.4;Susceptibility Factors;342
9.3.5;Drug Administration;343
9.3.6;Interference with Diagnostic tests;343
9.3.7;References;343
9.4;Chapter 50 Potassium perchlorate;345
9.4.1;General Information;345
9.4.2;Organs and Systems;345
9.4.3;References;345
9.5;Chapter 51 Protirelin;345
9.5.1;General Information;345
9.5.2;Organs and Systems;345
9.5.3;References;346
9.6;Chapter 52 Thionamides;346
9.6.1;General Information;346
9.6.2;Organs and Systems;347
9.6.3;Second-Generation Effects;351
9.6.4;Susceptibility Factors;353
9.6.5;Drug Administration;353
9.6.6;Drug–Drug Interactions;353
9.6.7;References;353
9.7;Chapter 53 Thyroid hormones;357
9.7.1;General Information;357
9.7.2;Organs and Systems;358
9.7.3;Long-Term Effects;361
9.7.4;Second-Generation Effects;361
9.7.5;Susceptibility Factors;361
9.7.6;Drug Administration;362
9.7.7;Drug–Drug Interactions;362
9.7.8;Monitoring Therapy;363
9.7.9;References;364
9.8;Chapter 54 Thyrotrophin and thyrotropin;366
9.8.1;General Information;366
9.8.2;Organs and Systems;366
9.8.3;References;366
10;Section 5 Insulins and other hypoglycemic drugs;368
10.1;Chapter 55 Aldose reductase inhibitors;370
10.1.1;General Information;370
10.1.2;Organs and Systems;370
10.1.3;References;370
10.2;Chapter 56 Alpha-glucosidase inhibitors;370
10.2.1;General Information;370
10.2.2;Organs and Systems;371
10.2.3;Second-Generation Effects;374
10.2.4;Drug–Drug Interactions;374
10.2.5;References;375
10.3;Chapter 57 Amylin analogues;377
10.3.1;General Information;377
10.3.2;Organs and Systems;378
10.3.3;Drug-drug interactions;378
10.3.4;References;378
10.4;Chapter 58 Biguanides;378
10.4.1;General Information;378
10.4.2;Organs and Systems;381
10.4.3;Second-Generation Effects;386
10.4.4;Susceptibility Factors;387
10.4.5;Drug Administration;387
10.4.6;Drug–Drug Interactions;388
10.4.7;References;389
10.5;Chapter 59 Blood glucose meters;393
10.5.1;General Information;393
10.5.2;Organs and Systems;394
10.5.3;References;394
10.6;Chapter 60 Dipeptidyl peptidase IV inhibitors;394
10.6.1;General information;394
10.6.2;Organs and Systems;395
10.6.3;Drug-drug interactions;395
10.6.4;References;395
10.7;Chapter 61 Glucagon;395
10.7.1;General Information;395
10.7.2;Organs and Systems;396
10.7.3;Susceptibility Factors;396
10.7.4;References;397
10.8;Chapter 62 Glucagon-like peptide-1;397
10.8.1;General Information;397
10.8.2;Organs and Systems;397
10.8.3;References;398
10.9;Chapter 63 Guar gum;398
10.9.1;General Information;398
10.9.2;Organs and Systems;398
10.9.3;References;398
10.10;Chapter 64 Incretin mimetics;399
10.10.1;General Information;399
10.10.2;Organs and Systems;399
10.10.3;Long-Term Effects;400
10.10.4;Drug administration;401
10.10.5;Drug-Drug Interactions;401
10.10.6;References;401
10.11;Chapter 65 Insulin;402
10.11.1;General Information;402
10.11.2;Organs and Systems;404
10.11.3;Long-Term Effects;414
10.11.4;Second-Generation Effects;414
10.11.5;Susceptibility Factors;415
10.11.6;Drug Administration;415
10.11.7;Drug–Drug Interactions;422
10.11.8;Interference with Diagnostic Tests;423
10.11.9;Management of adverse drug reactions;424
10.11.10;Monitoring Therapy;424
10.11.11;References;424
10.12;Chapter 65 Insulin aspart;433
10.12.1;General Information;433
10.12.2;Organs and Systems;434
10.12.3;References;434
10.13;Chapter 66 Insulin detemir;435
10.13.1;General Information;435
10.13.2;Organs and Systems;436
10.13.3;References;436
10.14;Chapter 67 Insulin glargine;436
10.14.1;General Information;436
10.14.2;Organs and Systems;437
10.14.3;Drug Administration;438
10.14.4;References;438
10.15;Chapter 68 Insulin lispro;439
10.15.1;General Information;439
10.15.2;Organs and Systems;440
10.15.3;Second-Generation Effects;442
10.15.4;Susceptibility Factors;442
10.15.5;Drug Administration;442
10.15.6;References;442
10.16;Chapter 69 Insulin-like growth factor (IGF-I);444
10.16.1;General Information;444
10.16.2;Organs and Systems;444
10.16.3;Long-Term Effects;445
10.16.4;References;445
10.17;Chapter 70 Meglitinides;445
10.17.1;General Information;445
10.17.2;Organs and Systems;448
10.17.3;Susceptibility Factors;449
10.17.4;Drug–Drug Interactions;449
10.17.5;References;450
10.18;Chapter 71 Sulfonylureas;452
10.18.1;General Information;452
10.18.2;Organs and Systems;454
10.18.3;Second-Generation Effects;459
10.18.4;Susceptibility Factors;460
10.18.5;Drug Administration;460
10.18.6;Drug–Drug Interactions;462
10.18.7;Management of adverse drug reactions;464
10.18.8;References;464
10.19;Chapter 72 Thiazolidinediones;469
10.19.1;General Information;469
10.19.2;Organs and Systems;472
10.19.3;Susceptibility Factors;479
10.19.4;Drug–Drug Interactions;479
10.19.5;References;480
11;Section 6 Other hormones and related drugs;486
11.1;Chapter 73 Calcitonin;488
11.1.1;General Information;488
11.1.2;Organs and Systems;488
11.1.3;Drug Administration;489
11.1.4;Drug–Drug Interactions;489
11.1.5;References;489
11.2;Chapter 74 Desmopressin;490
11.2.1;General Information;490
11.2.2;Organs and Systems;491
11.2.3;Second-Generation Effects;494
11.2.4;Susceptibility factors;494
11.2.5;Drug–Drug Interactions;494
11.2.6;References;495
11.3;Chapter 75 Follitropin;497
11.3.1;General Information;497
11.3.2;Organs and Systems;497
11.3.3;References;497
11.4;Chapter 76 Gonadorelin and analogues;497
11.4.1;General Information;497
11.4.2;Organs and Systems;498
11.4.3;Long-Term Effects;501
11.4.4;Second-Generation Effects;502
11.4.5;Drug Administration;502
11.4.6;Drug-Drug Interactions;502
11.4.7;Management of adverse drug reactions;502
11.4.8;References;502
11.5;Chapter 77 Gonadorelin antagonists;505
11.5.1;General Information;505
11.5.2;Organs and Systems;505
11.5.3;References;505
11.6;Chapter 78 Melatonin;506
11.6.1;General Information;506
11.6.2;Organs and Systems;506
11.6.3;Long-Term Effects;508
11.6.4;Drug Administration;508
11.6.5;Drug–Drug Interactions;508
11.6.6;References;509
11.7;Chapter 79 Oxytocin and analogues;509
11.7.1;General Information;509
11.7.2;Organs and Systems;510
11.7.3;Second-Generation Effects;510
11.7.4;References;511
11.8;Chapter 80 Parathyroid hormone and analogues;511
11.8.1;General Information;511
11.8.2;Organs and Systems;511
11.8.3;Long-Term Effects;512
11.8.4;Drug–Drug Interactions;512
11.8.5;References;512
11.9;Chapter 81 Somatostatin and analogues;513
11.9.1;General Information;513
11.9.2;Organs and Systems;514
11.9.3;Second-Generation Effects;516
11.9.4;Susceptibility Factors;517
11.9.5;Drug–Drug Interactions;517
11.9.6;References;517
11.10;Chapter 82 Somatropin (growth hormone);519
11.10.1;General Information;519
11.10.2;Organs and Systems;519
11.10.3;Long-Term Effects;524
11.10.4;Second-Generation Effects;525
11.10.5;Susceptibility Factors;525
11.10.6;Drug Administration;525
11.10.7;Drug–Drug Interactions;526
11.10.8;References;526
11.11;Chapter 83 Somatropin (growth hormone) receptor antagonists;530
11.11.1;General Information;530
11.11.2;Organs and Systems;530
11.11.3;Long-Term Effects;531
11.11.4;References;531
11.12;Chapter 84 Vasopressin and analogues;531
11.12.1;General Information;531
11.12.2;Organs and Systems;532
11.12.3;Drug Administration;533
11.12.4;References;534
11.13;Chapter 85 Vasopressin receptor antagonists;535
11.13.1;General Information;535
11.13.2;Organs and Systems;535
11.13.3;Drug-Drug Interactions;535
11.13.4;References;535
12;Section 7 Lipid – regulating drugs;538
12.1;Chapter 86 Acipimox;540
12.1.1;General Information;540
12.1.2;Organs and Systems;540
12.1.3;References;540
12.2;Chapter 87 Atorvastatin;540
12.2.1;General Information;540
12.2.2;Organs and Systems;540
12.2.3;Drug Administration;541
12.2.4;Drug–Drug Interactions;542
12.2.5;References;542
12.3;Chapter 88 Cerivastatin;543
12.3.1;General Information;543
12.3.2;Organs and Systems;544
12.3.3;Drug–Drug Interactions;544
12.3.4;References;544
12.4;Chapter 89 Ezetimibe;545
12.4.1;General Information;545
12.4.2;Organs and Systems;545
12.4.3;Drug-drug interactions;545
12.4.4;References;545
12.5;Chapter 90 Fibrates;546
12.5.1;General Information;546
12.5.2;Organs and Systems;546
12.5.3;Long-Term Effects;548
12.5.4;Second-Generation Effects;548
12.5.5;Drug–Drug Interactions;548
12.5.6;References;550
12.6;Chapter 91 Fish oils;552
12.6.1;General Information;552
12.6.2;Organs and Systems;552
12.6.3;Second-Generation Effects;553
12.6.4;Drug–Drug Interactions;553
12.6.5;References;553
12.7;Chapter 92 Fluvastatin;554
12.7.1;General Information;554
12.7.2;Organs and Systems;554
12.7.3;Drug Administration;555
12.7.4;Drug–Drug Interactions;555
12.7.5;References;555
12.8;Chapter 93 HMG coenzyme-A reductase inhibitors;555
12.8.1;General Information;555
12.8.2;Organs and Systems;556
12.8.3;Long-Term Effects;560
12.8.4;Drug–Drug Interactions;560
12.8.5;References;563
12.9;Chapter 94 Ion exchange resins;566
12.9.1;General Information;566
12.9.2;Organs and Systems;566
12.9.3;Drug–Drug Interactions;567
12.9.4;References;568
12.10;Chapter 95 Lorenzo's oil;568
12.10.1;General Information;568
12.10.2;Organs and Systems;569
12.10.3;References;569
12.11;Chapter 96 Lovastatin;569
12.11.1;General Information;569
12.11.2;Organs and Systems;569
12.11.3;Drug–Drug Interactions;569
12.11.4;References;570
12.12;Chapter 97 Nicotinic acid and derivatives;571
12.12.1;General Information;571
12.12.2;Organs and Systems;572
12.12.3;Drug Administration;574
12.12.4;Drug-Drug Interactions;574
12.12.5;References;575
12.13;Chapter 98 Pravastatin;576
12.13.1;General Information;576
12.13.2;Organs and Systems;576
12.13.3;Drug–Drug Interactions;576
12.13.4;References;577
12.14;Chapter 99 Probucol;577
12.14.1;General Information;577
12.14.2;Organs and Systems;577
12.14.3;References;577
12.15;Chapter 100 Simvastatin;577
12.15.1;General Information;577
12.15.2;Organs and Systems;578
12.15.3;Second-Generation Effects;579
12.15.4;Drug–Drug Interactions;579
12.15.5;References;580
13;Section 8 Endocrine and metabolic adverse effects of non-hormonal and non-metabolic drugs;582
13.1;Abacavir;584
13.2;Acetylsalicylic acid;584
13.3;Adrenaline;584
13.4;Albumin;584
13.5;Aldesleukin;584
13.6;Alemtuzumab;585
13.7;Alprazolam;585
13.8;Aminoglycoside antibiotics;585
13.9;Amiodarone;585
13.10;Amisulpride;589
13.11;Amoxapine;590
13.12;Amphetamines;590
13.13;Angiotensin-converting enzyme inhibitors;590
13.14;Antacids;590
13.15;Antiepileptic drugs;590
13.16;Antihistamines;593
13.17;Antiretroviral drugs;593
13.18;Apiaceae;595
13.19;Aripiprazole;595
13.20;Artesunate;596
13.21;Articaine;596
13.22;Ascorbic acid (vitamin C);596
13.23;Asparaginase;596
13.24;Azathioprine;596
13.25;Benazepril;596
13.26;Benzodiazepines;597
13.27;Beta2-adrenoceptor agonists;597
13.28;Beta-adrenoceptor antagonists;597
13.29;Beta-lactam antibiotics;598
13.30;Bile acids;599
13.31;Bisoprolol;599
13.32;Bisphosphonates;599
13.33;Bromocriptine;599
13.34;Bumetanide;599
13.35;Caffeine;599
13.36;Calcipotriol;599
13.37;Calcium channel blockers;599
13.38;Cannabinoids;600
13.39;Carbamazepine;600
13.40;Carbenoxolone;600
13.41;Carbonic anhydrase inhibitors;600
13.42;Cardiac glycosides;601
13.43;Carvedilol;602
13.44;Ceftriaxone;602
13.45;Celastraceae;602
13.46;Chlordiazepoxide;602
13.47;Chloroquine and hydroxychloroquine;602
13.48;Cibenzoline;603
13.49;Ciclosporin;603
13.50;Cimetidine;604
13.51;Citric acid and citrates;604
13.52;Clomipramine;604
13.53;Clonazepam;605
13.54;Clonidine and apraclonidine;605
13.55;Clozapine;605
13.56;Clusiaceae;606
13.57;Cocaine;606
13.58;Colchicine;607
13.59;Complementary and alternative medicine;607
13.60;Coumarin anticoagulants;607
13.61;Cucurbitaceae;607
13.62;Cyclophosphamide;607
13.63;Cytostatic and immunosuppressant drugs;608
13.64;Dexamfetamine;608
13.65;Dextromethorphan;608
13.66;Dextropropoxyphene;608
13.67;Diamorphine;608
13.68;Diazepam;608
13.69;Diazoxide;608
13.70;Disopyramide;609
13.71;Diuretics;609
13.72;Donepezil;611
13.73;Doxycycline;611
13.74;Efavirenz;611
13.75;Enalapril;611
13.76;Encainide;611
13.77;Enflurane;611
13.78;Ephedra, ephedrine, and pseudoephedrine;612
13.79;Erythropoietin, epoetin alfa, epoetin beta, epoetin gamma, and darbepoetin;612
13.80;Etacrynic acid;612
13.81;Etanercept;612
13.82;Ethambutol;612
13.83;Ethionamide and protionamide;612
13.84;Etomidate;612
13.85;Everolimus;612
13.86;Fenfluramine;612
13.87;Fentanyl;612
13.88;Fluconazole;613
13.89;Flumazenil;613
13.90;Fluoroquinolones;613
13.91;Fluorouracil;613
13.92;Fluoxetine;613
13.93;Flutamide;613
13.94;Fluvoxamine;614
13.95;Fructose and sorbitol;614
13.96;Furosemide;614
13.97;Gabapentin;614
13.98;Ganciclovir;614
13.99;Gatifloxacin;614
13.100;General anesthetics;615
13.101;Glycerol;615
13.102;Glycyrrhiza species (Fabaceae);615
13.103;Glycols;615
13.104;Gold and gold salts;615
13.105;Granulocyte colony-stimulating factor (G-CSF);615
13.106;Granulocyte–macrophage colony-stimulating factor (GM-CSF);615
13.107;Griseofulvin;616
13.108;Haemophilus influenzae type b (Hib) vaccine;616
13.109;Halogenated quinolines;616
13.110;Haloperidol;616
13.111;Heparins;617
13.112;Hydralazine;617
13.113;Ibuprofen;617
13.114;Imipenem;617
13.115;Immunoglobulins;617
13.116;Indapamide;617
13.117;Indinavir;617
13.118;Indometacin;618
13.119;Infliximab;618
13.120;Interferon alfa;618
13.121;Interferon beta;622
13.122;Interferon gamma;623
13.123;Interleukin-1;623
13.124;Interleukin-4;623
13.125;Interleukin-6;623
13.126;Iodinated contrast media;623
13.127;Iron salts;624
13.128;Isoniazid;625
13.129;Ketamine;625
13.130;Ketoconazole;625
13.131;Lamotrigine;625
13.132;Leflunomide;625
13.133;Levodopa and dopa decarboxylase inhibitors;625
13.134;Levofloxacin;626
13.135;Lidocaine;626
13.136;Linezolid;626
13.137;Lisinopril;626
13.138;Lithium;626
13.139;Local anesthetics;631
13.140;Lopinavir + ritonavir;632
13.141;Lorazepam;632
13.142;Lorcainide;632
13.143;Manganese;632
13.144;Maprotiline;632
13.145;Measles, mumps, and rubella vaccines;632
13.146;Mefloquine;632
13.147;Methadone;632
13.148;Methyldopa;632
13.149;Methylphenidate;633
13.150;Metoclopramide;633
13.151;Metronidazole;633
13.152;Miconazole;633
13.153;Minocycline;633
13.154;Minoxidil;633
13.155;Mitotane;633
13.156;Mizoribine;633
13.157;Moclobemide;634
13.158;Monoamine oxidase inhibitors;634
13.159;Morphine;634
13.160;Moxifloxacin;634
13.161;Nalidixic acid;634
13.162;Naloxone;634
13.163;Nabumetone;634
13.164;Nefazodone;634
13.165;Nelfinavir;634
13.166;Neuroleptic drugs;635
13.167;Nevirapine;641
13.168;Nicorandil;641
13.169;Nicotinic acid and derivatives;641
13.170;Nitrofurantoin;641
13.171;Nucleoside analogue reverse transcriptase inhibitors (NRTIs);641
13.172;Ofloxacin;642
13.173;Olanzapine;642
13.174;Omeprazole;645
13.175;Opioid analgesics;645
13.176;Oxaprozin;646
13.177;Pancreatic enzymes;646
13.178;Pantothenic acid derivatives;646
13.179;Paracetamol;646
13.180;Parenteral nutrition;646
13.181;Paroxetine;648
13.182;Penicillamine;648
13.183;Penicillins;648
13.184;Pentamidine;649
13.185;Phenylbutazone;649
13.186;Phenytoin and fosphenytoin;649
13.187;Phosphates;649
13.188;Photochemotherapy (PUVA);649
13.189;Pizotifen;649
13.190;Platinum-containing cytostatic drugs;649
13.191;Prazosin;650
13.192;Propafenone;650
13.193;Propofol;650
13.194;Protease inhibitors;652
13.195;Pyrazinamide;653
13.196;Pyritinol;653
13.197;Quetiapine;653
13.198;Quinine;654
13.199;Ramipril;654
13.200;Reboxetine;654
13.201;Reserpine;654
13.202;Rifamycins;654
13.203;Risperidone;655
13.204;Ritodrine;657
13.205;Roxithromycin;657
13.206;Salbutamol;657
13.207;Saquinavir;658
13.208;Selective serotonin re-uptake inhibitors (SSRIs);658
13.209;Selenium;658
13.210;Sertindole;658
13.211;Sertraline;658
13.212;Sirolimus;658
13.213;Smallpox vaccine;659
13.214;Sorafenib;659
13.215;Spironolactone;659
13.216;Stavudine;659
13.217;Sulfonamides;659
13.218;Sunitinib;659
13.219;Suramin;660
13.220;Tacrolimus;660
13.221;Tenofovir;661
13.222;Terbutaline;661
13.223;Tetracyclines;661
13.224;Thalidomide;662
13.225;Theophylline;662
13.226;Thiazide diuretics;662
13.227;Thiopental sodium;662
13.228;Tiabendazole;663
13.229;Tiagabine;663
13.230;Tiopronin;663
13.231;Topiramate;663
13.232;Tricyclic antidepressants;663
13.233;Trimethoprim and co-trimoxazole;664
13.234;Tripterygium wilfordii (Celastraceae);664
13.235;Troleandomycin;664
13.236;Tumor necrosis factor alfa;664
13.237;Valproic acid;664
13.238;Vancomycin;667
13.239;Verapamil;667
13.240;Vigabatrin;667
13.241;Vinca alkaloids;667
13.242;Vitamin A: Carotenoids;667
13.243;Vitamin A: Retinoids;667
13.244;Vitamin D analogues;668
13.245;Xipamide;668
13.246;Zidovudine;668
13.247;Ziprasidone;668
13.248;Zopiclone;668
13.249;References;668
14;Index of drug names;704